Study of new drug combo for extensive-stage small-cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have extensive-stage small-cell lung cancer (cancer that has spread to both lungs or beyond).
- You cannot have had any prior treatment for this cancer.
- You must be able to do your daily activities with little to no help (ECOG 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- You must have adequate organ function (kidneys, liver, heart, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a new combination of investigational drugs (HS-20093) for people with extensive-stage small cell lung cancer whose disease hasn't progressed after initial treatment. The goal is to see if this approach can keep the cancer from growing.
This study tests a new combination therapy for extensive-stage small cell lung cancer (cancer that has spread beyond the lung). The treatment includes an immunotherapy drug, a drug that blocks blood vessel growth to tumors, and chemotherapy. It aims to see how well this combination works in people who have not yet been treated for this cancer.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.